Core Viewpoint - The release of the "Clinical Practice Guidelines for Ion Radiation Therapy (2025 Edition)" and the "Quality Assurance Guidelines for Proton Radiation Therapy Systems (2025 Edition)" marks the establishment of systematic and comprehensive industry standards for high-end radiation therapy in China [1][2]. Group 1: Industry Standards and Contributions - The guidelines were developed by a team including experts from Guangzhou Taihe Hospital, part of Meizhong Jiahe Medical Technology Development Group, along with top public institutions [1]. - Meizhong Jiahe has been involved in the formulation of national guidelines four times in recent years, contributing to six national standard outcomes, indicating a shift from occasional participation to a sustained and systematic role in standard-setting [1][2]. - Industry experts view participation in national standard formulation as a certification of technical and quality systems, reflecting long-term accumulation of capabilities [1]. Group 2: Competitive Position and Growth Potential - With stricter regulations and detailed standards, the industry is entering a phase where stronger capabilities lead to faster expansion, benefiting Meizhong Jiahe in approvals, collaborations, academic branding, and clinical appeal [2]. - All four proton therapy rooms at Guangzhou Taihe Hospital are now operational, leading to rapid growth in treatment volume and solidifying its position as a particle center in South China [2]. - Meizhong Jiahe's long-term performance, marked by its four entries into national guidelines and six contributions, positions it among the few social medical entities in the top tier of the industry, enhancing its competitive advantage in high-end radiation therapy [2].

Core Viewpoint - The company, International Medicine, plans to raise up to 1.008 billion yuan through a private placement of shares, with the funds allocated for smart healthcare projects, the second phase of the proton therapy center, and to supplement working capital [1][2]. Group 1: Fundraising and Project Allocation - The fundraising will support the transition of the company's business from traditional medical services to high-end radiation therapy, establishing a synergistic business model of "comprehensive diagnosis + precise radiation therapy" [1]. - A significant portion of the raised funds will be directed towards the smart healthcare project, utilizing idle spaces to enhance asset utilization and generate high-value healthcare services [1]. - The second phase of the proton therapy center aims to establish the first operational proton therapy project in Northwest China [2]. Group 2: Financial Performance and Debt Management - The company has experienced substantial losses over recent years, with cumulative losses of 2.621 billion yuan from 2021 to 2024 [3]. - In the first three quarters of 2025, the company reported a revenue of 2.995 billion yuan, a year-on-year decline of 16.94%, and a net loss of 294 million yuan, representing a 38.45% increase in losses compared to the previous year [3]. - The company has a high debt ratio of 68.80%, and the fundraising is expected to help reduce this ratio and optimize the capital structure [1].